Cargando…

Initial results of efficacy and safety of Sofosbuvir among Pakistani Population: A real life trial - Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS)

OBJECTIVE: The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase approved for the treatment of chronic HCV infection with genotypes 1 – 4. The objective of the study was to evaluate the interim results of efficacy and safety of regimens contai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azam, Zahid, Shoaib, Muhammad, Javed, Masood, Sarwar, Muhammad Adnan, Shaikh, Hafeezullah, Khokhar, Nasir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368328/ https://www.ncbi.nlm.nih.gov/pubmed/28367171 http://dx.doi.org/10.12669/pjms.331.12352

Ejemplares similares

Rapid virological&End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C
por: Siddique, Muhammad Shoaib, et al.
Publicado: (2017)

Hepatitis C eradication with sofosbuvir leads to significant metabolic changes
por: Morales, Amilcar L, et al.
Publicado: (2016)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
por: Thalhammer, Julian, et al.
Publicado: (2021)

Efficacy and Safety of Sofosbuvir-Velpatasvir combination in Hepatitis C Virus-infected Pakistani Patients without Cirrhosis or with Compensated Cirrhosis: A Prospective, Open-label Interventional Trial
por: Butt, Nazish, et al.
Publicado: (2020)

Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference?
por: Sarwar, Shahid, et al.
Publicado: (2017)

Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience
por: Butt, Zamir, et al.
Publicado: (2019)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

Sofosbuvir: A Potential Treatment for Ebola
por: Reznik, Sandra E., et al.
Publicado: (2018)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Potential Use of Sofosbuvir in the Prophylaxis for Rabies
por: Reznik, Sandra E., et al.
Publicado: (2020)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)

Retinopathy and Uveitis Associated with Sofosbuvir Therapy for Chronic Hepatitis C Infection
por: Chin-Loy, Katrina, et al.
Publicado: (2016)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
por: Heo, Jeong, et al.
Publicado: (2023)

Sofosbuvir Has Come Out of the Magic Box
por: Alavian, Seyed Moayed
Publicado: (2013)

A bibliometric analysis of the global research on sofosbuvir
por: Hernández-Vásquez, Akram, et al.
Publicado: (2017)

Use of sofosbuvir in chronic kidney disease: Is it necessary?
por: Lim, Tae Seop, et al.
Publicado: (2017)

Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
por: Ashraf, Taha, et al.
Publicado: (2017)

Public funding for transformative drugs: the case of sofosbuvir
por: Barenie, Rachel E., et al.
Publicado: (2021)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Correction: Retinopathy and Uveitis Associated with Sofosbuvir Therapy for Chronic Hepatitis C Infection
por: Chin Loy, Katrina, et al.
Publicado: (2016)

Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial
por: Ahmed, Sarfraz, et al.
Publicado: (2022)

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control
por: Joharji, Hala, et al.
Publicado: (2022)

Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C
por: Sarkar, Souvik, et al.
Publicado: (2015)

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
por: Leleu, H, et al.
Publicado: (2015)

Sofosbuvir, a Significant Paradigm Change in HCV Treatment
por: McQuaid, Thomas, et al.
Publicado: (2015)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
por: Premji, Resmi, et al.
Publicado: (2015)

Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir
por: Shenk, Mary Elizabeth Reed, et al.
Publicado: (2018)

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
por: Childs-Kean, Lindsey M, et al.
Publicado: (2019)

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection
por: Anna, Linda Zignego, et al.
Publicado: (2018)

Sofosbuvir induced leucocytoclasic vasculitis: a case report
por: Campione, Elena, et al.
Publicado: (2019)

Sofosbuvir as a potential option for the treatment of COVID-19
por: Nourian, Anahid, et al.
Publicado: (2020)

Sofosbuvir for COVID-19 infection: A potential candidate
por: Gupta, Rohit, et al.
Publicado: (2020)

The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD
por: Gabbia, Daniela, et al.
Publicado: (2022)

Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
por: Ren, Xiao-Dan, et al.
Publicado: (2022)

Successful Eradication of Hepatitis-C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients
por: Ali, Bushra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_brjufl4fjtg76rcrd7mmmardvc